NAD+ and GLP-1 medications like semaglutide and tirzepatide can generally be combined, and a growing number of telehealth weight loss patients are stacking the two on purpose: NAD+ to support cellular energy while GLP-1s reduce appetite and calorie intake. There’s no established drug interaction between them, but timing, dosing, and expectations matter, and this guide breaks down what the current evidence and clinical practice actually support.
Why Patients Combine NAD+ and GLP-1 Therapy
GLP-1 receptor agonists work by slowing gastric emptying and signaling fullness to the brain, which is highly effective for weight loss but comes with a well-documented tradeoff: significant calorie restriction can leave patients feeling fatigued, especially during dose titration. Some patients also report a drop in lean muscle mass alongside fat loss, which compounds the sense of low energy.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in mitochondrial energy production and cellular repair. Clinics have started offering it alongside GLP-1 protocols specifically to address that fatigue complaint, and some patients report feeling more energized and recovering faster from workouts when the two are used together — though this is based on patient-reported outcomes and clinical experience rather than a dedicated head-to-head trial of the combination.
How NAD+ and GLP-1s Work Together
The two therapies work through entirely separate mechanisms, which is part of why they’re considered compatible. NAD+ supports the electron transport chain that mitochondria use to generate ATP, the cellular energy currency your body relies on for everything from muscle contraction to cognitive function. GLP-1 medications, by contrast, act on receptors in the gut and brain to regulate appetite and glucose metabolism.
Because NAD+ isn’t metabolized through the same pathways as semaglutide or tirzepatide, there’s no known pharmacokinetic interaction — one doesn’t speed up or slow down how the body processes the other. That said, “no known interaction” is not the same as “extensively studied together,” so patients should still loop in a prescribing clinician before stacking any two therapies, particularly if other medications or health conditions are in the picture.
Timing and Dosing When Combining NAD+ and GLP-1 Therapy
Most clinics that offer both therapies keep the dosing schedules independent rather than syncing them to a single visit. A typical approach looks like:
- GLP-1 injections (semaglutide or tirzepatide) continue on their standard weekly schedule, following the titration plan a provider sets.
- NAD+ is dosed separately, commonly as a subcutaneous injection or IV a few times per week during periods when fatigue is most noticeable, such as early titration or during a dose increase.
- Injection sites are typically rotated and spaced apart if both are self-administered subcutaneously on the same day, to reduce local irritation.
There’s no evidence that taking NAD+ at a specific time relative to a GLP-1 dose changes its effectiveness, so most protocols prioritize what’s sustainable for the patient over a rigid schedule.
Potential Side Effects and Safety Considerations
Combining therapies means combining side effect profiles, even if the drugs don’t interact directly. GLP-1s commonly cause nausea, constipation, or reflux, particularly during dose increases. NAD+ injections can cause flushing, mild nausea, or injection-site discomfort, and IV NAD+ in particular is sometimes associated with chest tightness or a racing heartbeat during infusion if given too quickly.
Because nausea overlaps between the two, patients starting both at once may have a harder time identifying which therapy is causing a given symptom. Some clinicians recommend starting GLP-1 therapy first, letting the patient stabilize on it, and introducing NAD+ afterward so any new symptom is easier to trace. Patients with cardiovascular conditions, pregnant or breastfeeding patients, and anyone on multiple other medications should have this conversation directly with their prescribing provider before combining the two.
Frequently Asked Questions
Is it safe to take NAD+ while on semaglutide or tirzepatide?
For most healthy adults, yes — there’s no known drug interaction between NAD+ and GLP-1 medications like semaglutide or tirzepatide, since they work through unrelated pathways. Patients with cardiovascular disease, other chronic conditions, or multiple prescriptions should confirm with their provider first.
Will NAD+ help with GLP-1 fatigue?
Many patients report improved energy when adding NAD+ during GLP-1 therapy, likely because it supports the mitochondrial energy production that can lag during significant calorie restriction. This is based on clinical experience and patient reports rather than a controlled trial specifically testing the combination.
Does NAD+ affect GLP-1 weight loss results?
NAD+ does not change how semaglutide or tirzepatide work on appetite or metabolism, and it isn’t a weight loss agent on its own. Its role in a combined protocol is supporting energy and recovery, not accelerating fat loss.
If fatigue or muscle recovery has been the hardest part of your GLP-1 journey, talk to a RespondWell provider about whether adding NAD+ makes sense for your protocol. Visit the RespondWell shop to see current treatment options and get started with a personalized consultation.